View in EDS

Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment: An expert view

Saved in:
Bibliographic Details
Title: Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment: An expert view
Authors: Pere Gascón, Ahmad Awada, Peeter Karihtala, Sylvie Lorenzen, Christoph Minichsdorfer
Source: Wien Klin Wochenschr
Publisher Information: Springer Science and Business Media LLC, 2023.
Publication Year: 2023
Subject Terms: G-CSF prophylaxis, Evidence-Based Medicine, Dose-Response Relationship, Drug, Febrile neutropenia, Antineoplastic Agents, Review Article, Sciences bio-médicales et agricoles, 3. Good health, Survival Rate, Dose-Response Relationship, Drug [MeSH], Antineoplastic Agents/adverse effects [MeSH], Febrile Neutropenia/prevention, Febrile Neutropenia/chemically induced [MeSH], Humans [MeSH], Neoplasms/mortality [MeSH], Treatment Outcome [MeSH], Granulocyte Colony-Stimulating Factor/administration, Survival Rate [MeSH], Chemotherapy-Induced Febrile Neutropenia/etiology [MeSH], Evidence-Based Medicine [MeSH], Chemotherapy dose intensity, Cancer supportive care, Granulocyte Colony-Stimulating Factor/therapeutic use [MeSH], Neoplasms/drug therapy [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Chemotherapy-Induced Febrile Neutropenia/prevention, Treatment Outcome, Neoplasms, Granulocyte Colony-Stimulating Factor, Humans, Chemotherapy-Induced Febrile Neutropenia, Febrile Neutropenia
Description: Summary Background Febrile neutropenia (FN) is a relatively common complication of cytotoxic chemotherapy. Prophylaxis with granulocyte colony-stimulating factor (G-CSF) can prevent FN and chemotherapy dose delays and enable the use of the higher dose intensities associated with a survival benefit; however, G‑CSF is not always used optimally. Summary Five medical oncologists with a special interest in supportive care met to discuss the evidence for prophylaxis with G‑CSF to improve survival in cancer patients, identify reasons why this is not always done, and suggest potential solutions. The dose intensity of chemotherapy is critical for maximizing survival in cancer patients but may be reduced as a result of hematological toxicity, such as FN. Use of G‑CSF has been shown to increase the chances of achieving the planned dose intensity in various cancers, including early-stage breast cancer and non-Hodgkin lymphoma. All physicians treating cancer patients should consider the use of G‑CSF prophylaxis in patients receiving chemotherapy, paying particular attention to patient-related risk factors. Key messages Strategies to optimize G‑CSF use include educating medical oncologists and pharmacists on the appropriate use of G‑CSF and informing patients about the efficacy of G‑CSF and its potential adverse effects. It is hoped that the evidence and opinions presented will help to encourage appropriate use of G‑CSF to support cancer patients at risk of FN in achieving the best possible outcomes from chemotherapy.
Document Type: Article
Other literature type
File Description: 1 full-text file(s): application/pdf
Language: English
ISSN: 1613-7671
0043-5325
DOI: 10.1007/s00508-023-02300-6
Access URL: https://pubmed.ncbi.nlm.nih.gov/38010512
https://repository.publisso.de/resource/frl:6518633
Rights: CC BY
Accession Number: edsair.doi.dedup.....f063d6e5a3896b1515e7807d02277f0c
Database: OpenAIRE
Description
Abstract:Summary Background Febrile neutropenia (FN) is a relatively common complication of cytotoxic chemotherapy. Prophylaxis with granulocyte colony-stimulating factor (G-CSF) can prevent FN and chemotherapy dose delays and enable the use of the higher dose intensities associated with a survival benefit; however, G‑CSF is not always used optimally. Summary Five medical oncologists with a special interest in supportive care met to discuss the evidence for prophylaxis with G‑CSF to improve survival in cancer patients, identify reasons why this is not always done, and suggest potential solutions. The dose intensity of chemotherapy is critical for maximizing survival in cancer patients but may be reduced as a result of hematological toxicity, such as FN. Use of G‑CSF has been shown to increase the chances of achieving the planned dose intensity in various cancers, including early-stage breast cancer and non-Hodgkin lymphoma. All physicians treating cancer patients should consider the use of G‑CSF prophylaxis in patients receiving chemotherapy, paying particular attention to patient-related risk factors. Key messages Strategies to optimize G‑CSF use include educating medical oncologists and pharmacists on the appropriate use of G‑CSF and informing patients about the efficacy of G‑CSF and its potential adverse effects. It is hoped that the evidence and opinions presented will help to encourage appropriate use of G‑CSF to support cancer patients at risk of FN in achieving the best possible outcomes from chemotherapy.
ISSN:16137671
00435325
DOI:10.1007/s00508-023-02300-6